Preferred Label : Befotertinib;
NCIt definition : An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant
form T790M, with potential antineoplastic activity. Upon administration, befotertinib
specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation,
which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing
tumor cells. Compared to some other EGFR inhibitors, befotertinib may have therapeutic
benefits in tumors with T790M-mediated drug resistance. EGFR, a receptor tyrosine
kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation
and tumor vascularization.;
UNII : 0XT2CPR891;
InChIKey : USOCZVZOXKTJTI-UHFFFAOYSA-N;
CAS number : 1835667-63-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1835667-63-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : D 0316; D-0316;
NCI Metathesaurus CUI : CL935820;
Origin ID : C175747;
UMLS CUI : C5446709;
Semantic type(s)
- concept_is_in_subset
- has_target
